NasdaqGM - Nasdaq Real Time Price USD

Ardelyx, Inc. (ARDX)

6.45 -0.29 (-4.30%)
At close: June 7 at 4:00 PM EDT
6.45 0.00 (0.00%)
After hours: June 7 at 7:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
159,110.00
124,456.00
52,158.00
10,097.00
7,571.00
--
Cost of Revenue
23,386.00
17,795.00
4,117.00
1,000.00
145.00
--
Gross Profit
135,724.00
106,661.00
48,041.00
9,097.00
7,426.00
--
Operating Expense
197,614.00
169,937.00
111,800.00
163,443.00
98,206.00
--
Operating Income
-61,890.00
-63,276.00
-63,759.00
-154,346.00
-90,780.00
--
Net Non Operating Interest Income Expense
-10,935.00
-8,874.00
-5,073.00
-4,502.00
-5,099.00
--
Other Income Expense
7,667.00
6,630.00
1,633.00
687.00
1,568.00
--
Pretax Income
-65,158.00
-65,520.00
-67,199.00
-158,161.00
-94,311.00
--
Tax Provision
654.00
547.00
8.00
4.00
2.00
--
Net Income Common Stockholders
-65,812.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
--
Diluted NI Available to Com Stockholders
-65,812.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
--
Basic EPS
-0.28
-0.30
-0.42
-1.52
-1.05
--
Diluted EPS
-0.28
-0.30
-0.42
-1.52
-1.05
--
Basic Average Shares
225,841.96
219,331.25
158,690.08
104,205.65
89,582.14
--
Diluted Average Shares
225,841.96
219,331.25
158,690.08
104,205.65
89,582.14
--
Total Operating Income as Reported
-61,890.00
-63,276.00
-63,759.00
-154,346.00
-90,780.00
--
Total Expenses
221,000.00
187,732.00
115,917.00
164,443.00
98,351.00
--
Net Income from Continuing & Discontinued Operation
-65,812.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
--
Normalized Income
-65,812.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
--
Interest Expense
10,935.00
8,874.00
5,073.00
4,502.00
5,099.00
--
Net Interest Income
-10,935.00
-8,874.00
-5,073.00
-4,502.00
-5,099.00
--
EBIT
-54,223.00
-56,646.00
-62,126.00
-153,659.00
-89,212.00
--
EBITDA
-52,493.00
-55,354.00
-60,982.00
-150,852.00
-86,671.00
--
Reconciled Cost of Revenue
23,386.00
17,795.00
4,117.00
1,000.00
145.00
--
Reconciled Depreciation
1,730.00
1,292.00
1,144.00
2,807.00
2,541.00
--
Net Income from Continuing Operation Net Minority Interest
-65,812.00
-66,067.00
-67,207.00
-158,165.00
-94,313.00
--
Normalized EBITDA
-52,493.00
-55,354.00
-60,982.00
-150,852.00
-86,671.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
12/31/2019 - 6/19/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CUE Cue Biopharma, Inc.
1.4800
-8.64%
 
AGEN Agenus Inc.
16.60
+0.24%
 
AKBA Akebia Therapeutics, Inc.
1.0600
-0.93%
 
IOVA Iovance Biotherapeutics, Inc.
7.78
-4.42%
 
TGTX TG Therapeutics, Inc.
15.85
+0.25%
 
MCRB Seres Therapeutics, Inc.
0.6140
-28.03%
 
XFOR X4 Pharmaceuticals, Inc.
1.0100
-0.98%
 
AXSM Axsome Therapeutics, Inc.
73.90
-1.15%
 
IBRX ImmunityBio, Inc.
6.10
+0.16%
 
MDGL Madrigal Pharmaceuticals, Inc.
244.34
+1.24%